Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.
CR Sanjiu released its unaudited financial results for the first quarter of 2025, reporting a decline in revenue and net profit compared to the same period in 2024. Despite the drop in revenue and profit, the company experienced a significant increase in cash and cash equivalents, indicating strong cash flow management. The financial results highlight a substantial growth in total assets and liabilities, reflecting ongoing expansion efforts. Stakeholders are advised to exercise caution, as these figures are unaudited and may be subject to adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd, a subsidiary of China Resources Pharmaceutical Group Ltd, operates in the pharmaceutical industry. It is primarily involved in the production and distribution of medical and pharmaceutical products, with its shares listed on the Shenzhen Stock Exchange.
YTD Price Performance: -19.26%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.51B
See more data about 3320 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue